Jay A. Barth

Chief Medical Officer at Amicus Therapeutics, Inc.

Jay A. Barth

Jay A. Barth

Chief Medical Officer at Amicus Therapeutics, Inc.

Overview
Career Highlights

PTC Therapeutics, Inc.
Merck & Co., Inc.

RelSci Relationships

2060

Birthday

1964

Age

55

Contact Data
Trying to get in touch with Jay A. Barth? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Jay A. Barth likely has professional access to. A relationship does not necessarily indicate a personal connection.

Former Chief Financial Officer & Secretary at Amicus Therapeutics, Inc.

Relationship likelihood: Strong

Chairman of the Board, Chief Executive Officer at Amicus Therapeutics, Inc.

Relationship likelihood: Strong

President, Chief Operating Officer & Director at Amicus Therapeutics, Inc.

Relationship likelihood: Strong

Chief Financial Officer at Amicus Therapeutics, Inc.

Relationship likelihood: Strong

Chief Portfolio Officer at Amicus Therapeutics, Inc.

Relationship likelihood: Strong

Chief Scientific Officer at Amicus Therapeutics, Inc.

Relationship likelihood: Average

Secretary, Chief Legal Officer & General Counsel at Amicus Therapeutics, Inc.

Relationship likelihood: Average

General Manager at Scioderm, Inc.

Relationship likelihood: Average

Co-Founder at PTC Therapeutics, Inc.

Relationship likelihood: Average

Founder at PTC Therapeutics, Inc.

Relationship likelihood: Average

Paths to Jay A. Barth
Potential Connections via
Relationship Science
You
Jay A. Barth
Chief Medical Officer at Amicus Therapeutics, Inc.
Education
B.A.

Columbia University is one of the world's most important centers of research and at the same time a distinctive and distinguished learning environment for undergraduates and graduate students in many scholarly and professional fields. The University recognizes the importance of its location in New York City and seeks to link its research and teaching to the vast resources of a great metropolis. It seeks to attract a diverse and international faculty and student body, to support research and teaching on global issues, and to create academic relationships with many countries and regions. It expects all areas of the university to advance knowledge and learning at the highest level and to convey the products of its efforts to the world.

MD

The University of Pennsylvania is the oldest and one of the finest medical schools in the United States. Penn is rich in tradition and heritage and at the same time consistently at the forefront of new developments and innovations in medical education and research. Since its founding in 1765 the School has been a strong presence in the community and prides itself on educating the leaders of tomorrow in patient care, biomedical research, and medical education. At Penn academic excellence, as well as compassion for the patients we are privileged to serve, are stressed. Skillful compassion is truly a hallmark of the Penn learning experience. The Perelman School of Medicine at the University of Pennsylvania consistently ranks among the top five in US News and World Report’s rankings of research-oriented medical schools.

Memberships
Member
Current

TO CARRY OUT THE EDUCATIONAL, PRACTICE, AND RESEARCH INTERESTS OF THE AGA MEMBERS.

Member
Current

TO ADVANCE THE PRACTICE, STUDY AND SCIENCE OF GASTROENTEROLOGY

Career History
Chief Medical Officer
2014 - Current

Amicus Therapeutics, Inc. is a biotechnology company, which is engaged in the discovery, development and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.

Executive Director, Clinical Development
2009 - 2014

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel medicines using its expertise in RNA biology. The company's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders and oncology. It is focused on developing treatments to fundamentally change the lives of patients living with rare genetic disorders. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Executive Director-Clinical Research
2007 - 2008

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Jay A. Barth. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Jay A. Barth's profile does not indicate a business or promotional relationship of any kind between RelSci and Jay A. Barth.
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/person/jay-a-barth-4881730
  • https://relationshipscience.com/person/jay-a-barth-4881730